(CercleFinance.com) – Genentech, the biotechnology subsidiary of Roche, announced on Friday that the US FDA has approved Lunsumio for the treatment of relapsed or refractory follicular lymphoma in adults.
Lunsumio, a bispecific antibody, should be available soon in the United States.
Despite recent advances in research, follicular lymphoma is a disease that is often characterized by relapses or even worsening of the patient’s condition despite currently available treatments.
In a phase II clinical study, Lunsumio showed an 80% response rate in treated patients, the majority of whom (57%) maintained a favorable response for at least 18 months.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
